Granulocyte colony-stimulating factor affects serum levels of soluble interleukin-2 receptors after allogeneic stem cell transplantation

Haematologica

Volumn 90, Issue 3, 2005, Pages 427-429

  Remberger, Mats ^a   Sundberg, Berit ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BMT; Cytokines; G CSF; GVHD

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; SOLUBILITY; TRANSPLANTATION, HOMOLOGOUS;

EID: 15244349529     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony- stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000;96:80-5.
2. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD grades II-IV. Bone Marrow Transplant 2003;32:217-23.
3. Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte-colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22:416-23.
4. Fernandez-Botran R, Chilton PM, Ma Y. Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv Immunol 1996;63:269-336:
5. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998;66:863-71.
6. Remberger M, Ringdén O, Blau I, Ottinger H, Kremens B, Kiehl MG, et al. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells with bone marrow using unrelated donors. Blood 2001;98:1739-45.
7. Kobayashi S, Imamura M, Hashino S, Noto S, Mori A, Tanaka J, et al. Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-α levels after allogeneic bone marrow transplantation. Leuk Lymphoma 1999;33:559-66.
8. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL, Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-9.
9. Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation 2000;69:691-3.